One of the building blocks for newly launched Clasp Therapeutics Corp. is making the right patient choices for treatment. If those who receive the company’s therapy are correctly identified, CEO Robert Ross told BioWorld, it will have a profound effect on outcomes. The missing link in cancer treatment, Ross added, was how to identify a patient, something he said Clasp is able to do.
University of Nebraska has described SF-2523 derivatives acting as dual inhibitors of bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) and phosphatidylinositol 3-kinase (PI3K) reported to be useful for the treatment of medulloblastoma and fibrosis.
China Pharmaceutical University scientists have published details on the discovery and preclinical evaluation of a glutathione peroxidase 4 (GPX4) and cyclin-dependent kinase (CDK) dual inhibitor being developed for the treatment of cancer.
Aptamer Sciences Inc. has filed an IND application with the Korean Ministry of Food and Drug Safety seeking clearance to conduct a phase I trial of AST-201 in patients with GPC3-positive advanced solid tumors.
Previous research has shown that adenosine impairs antitumor immunity, and high levels of adenosine and CD73 have been associated with poor prognosis in cancer.
Researchers from Foghorn Therapeutics Inc. recently presented preclinical data for FHD-609, a heterobifunctional degrader of BRD9 designed for the treatment of sarcoma. Synthesis and optimization of a series of first-generation compounds led to the identification of FHD-609 as a rapid, selective and highly potent BRD9 degrader, with high plasma stability and acceptable solubility.
China’s National Medical Products Administration has cleared China Grand Pharmaceutical and Healthcare Holdings Ltd. to advance radiopharmaceutical agent ITM-11 (177Lu-edotreotide) to phase III trials in gastroenteropancreatic-neuroendocrine tumors
RSS
